B. Riley upgraded Mirati Therapeutics to Buy from Neutral with an unchanged price target of $45.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MRTX:
- Mirati Therapeutics 9.7M share Spot Secondary priced at $27.80
- Mirati Therapeutics price target raised to $62 from $56 at Oppenheimer
- Mirati Therapeutics reports Q2 EPS ($3.04), consensus ($3.17)
- Mirati Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Updates
- Mirati Therapeutics announces $250M common stock offering